Browsing by Author "Uslu S."
Now showing 1 - 18 of 18
Results Per Page
Sort Options
Item Evaluation of the relationship between inducible nitric oxide synthase (iNOS) activity and effects of melatonin in experimental osteoporosis in the rat(2006) Oktem G.; Uslu S.; Vatansever S.H.; Aktug H.; Yurtseven M.E.; Uysal A.Inducible nitric oxide synthase (iNOS) plays a critical role in the pathogenesis of osteoporosis. iNOS generates nitric oxide (NO), a free radical contributing to the imbalance between bone formation and resorption caused by estrogen depletion. Melatonin is the major product of the pineal gland which is known to diminish iNOS expression and NO production significantly. The aim of this study was to determine the distribution of iNOS and the amount of apoptotic cells after melatonin treatment in ovariectomized rats. Since previous studies have shown that constitution of bone formation is primarily sustained in nucleus pulposus and epiphyseal cartilage, experiments were carried out on nucleus pulposus and epiphyseal cartilage; additional quantitation of osteoblasts and osteoclasts were evaluated on vertebral area as well. Vertebral sections of ovariectomized rats were obtained from formalin-fixed and parafin-embedded blocks. iNOS expression and quantitation of apoptotic cells in nucleus pulposus and epiphyseal cartilage were evaluated using indirect immunoperoxidase and TUNEL techniques, respectively. The number of osteoclasts and osteoblasts in trabecular bone was determined using histomorphometry. Ovariectomy increased iNOS expression and the number of apoptotic cells in nucleus pulposus and epiphyseal cartilage, whereas a 4-week treatment with melatonin (10 mg/kg/day) resulted in the reduction of both effects. These data indicate that there is strong influence of melatonin application on expression of iNOS, apoptosis, osteoclast and osteoblast numbers after ovariectomy. In conclusion, melatonin besides its usual use as an antiaging hormone, may also be an effective hormone in treatment of bone changes in estrogen deficiency states. © Springer-Verlag 2006.Item COVID-19: vaccination vs. hospitalization(Springer Science and Business Media Deutschland GmbH, 2022) Uzun O.; Akpolat T.; Varol A.; Turan S.; Bektas S.G.; Cetinkaya P.D.; Dursun M.; Bakan N.; Ketencioglu B.B.; Bayrak M.; Baris S.A.; Guner R.; Gunal O.; Nural S.; Deniz P.P.; Toprak O.B.; Ozkan G.; Gumus A.; Kerget F.; Ercelik M.; Ataoglu O.; Yuksel A.; Ates G.; Kutsoylu O.E.; Kose N.; Kizilirmak D.; Keskin S.; Gultekin O.; Coskun N.; Yilmaz E.S.; Uslu S.; Basyigit İ.; Ergan B.; Deveci F.; Yakar M.N.; Zuhur C.; Sagcan G.; Yuce Z.T.; Kuluozturk M.; Sezgin M.E.; Sezgin E.N.A.; Havlucu Y.; Cuhadaroglu C.; Kilinc O.; Boyaci H.; Altunay H.; Akti M.; Dursun Z.B.; Kalem A.K.; Isik S.A.; Akyildiz L.; Aykac N.; Almaz M.S.; Kokturk N.; Itil O.Objective: Vaccination is the most efficient way to control the coronavirus disease 2019 (COVID-19) pandemic, but vaccination rates remain below the target level in most countries. This multicenter study aimed to evaluate the vaccination status of hospitalized patients and compare two different booster vaccine protocols. Setting: Inoculation in Turkey began in mid-January 2021. Sinovac was the only available vaccine until April 2021, when BioNTech was added. At the beginning of July 2021, the government offered a third booster dose to healthcare workers and people aged > 50 years who had received the two doses of Sinovac. Of the participants who received a booster, most chose BioNTech as the third dose. Methods: We collected data from 25 hospitals in 16 cities. Patients hospitalized between August 1 and 10, 2021, were included and categorized into eight groups according to their vaccination status. Results: We identified 1401 patients, of which 529 (37.7%) were admitted to intensive care units. Nearly half (47.8%) of the patients were not vaccinated, and those with two doses of Sinovac formed the second largest group (32.9%). Hospitalizations were lower in the group which received 2 doses of Sinovac and a booster dose of BioNTech than in the group which received 3 doses of Sinovac. Conclusion: Effective vaccinations decreased COVID-19-related hospitalizations. The efficacy after two doses of Sinovac may decrease over time; however, it may be enhanced by adding a booster dose. Moreover, unvaccinated patients may be persuaded to undergo vaccination. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.Item Neonatal Resuscitation Practices in Turkey: A Survey of the Turkish Neonatal Society and the Union of European Neonatal and Perinatal Societies(AVES, 2023) Okulu E.; Koç E.; Erdeve Ö.; Akdağ A.; Aktaş S.; Aydemir Ö.; Aygün C.; Bayraktar B.T.; Cebeci B.; Çelik H.T.; Çelik K.; Engür D.; Ertuğrul S.; Fettah N.D.; Gültekin N.D.; Güçyetmez Z.Ş.T.; Gülen P.; Hirfanoğlu İ.M.; İnce Z.; Kader Ş.; Kahvecioğlu D.; Kanburoğlu M.K.; Karagöl B.S.; Kılıç İ.; Koroğlu Ö.A.; Melekoğlu N.A.; Narter F.; Olukman Ö.; Ongun H.; Ovalı F.; Özer E.A.; Özkan E.Ö.; Öztürk D.Y.; Özüdoğru E.; Sarıcı D.; Satar M.; Takçı Ş.; Tanrıverdi S.; Taşkın E.; Tayman C.; Tekgündüz K.Ş.; Tunç G.; Türkmen M.K.; Tüzün F.; Uslu S.; Ünal S.; Ünkar Z.A.; Yaman A.; Yaşa B.; Yıldırım Ş.; Yılmaz A.; Yılmaz F.H.; Yücesoy E.Objective: Optimal care in the delivery room is important to decrease neonatal morbidity and mortality. We aimed to evaluate neonatal resuscitation practices in Turkish centers. Materials and Methods: A cross-sectional survey consisted of a 91-item questionnaire focused on delivery room practices in neonatal resuscitation and was sent to 50 Turkish centers. Hospitals with <2500 and those with ≥2500 births/year were compared. Results: In 2018, approximately 240 000 births occurred at participating hospitals with a median of 2630 births/year. Participating hospitals were able to provide nasal continuous-positive- airway-pressure/high-flow nasal cannula, mechanical ventilation, high-frequency oscillatory ventilation, inhaled nitric oxide, and therapeutic hypothermia similarly. Antenatal counseling was routinely performed on parents at 56% of all centers. A resuscitation team was present at 72% of deliveries. Umbilical cord management for both term and preterm infants was similar between centers. The rate of delayed cord clamping was approximately 60% in term and late preterm infants. Thermal management for preterm infants (<32 weeks) was similar. Hospitals had appropriate equipment with similar rates of interventions and management, except conti nuous-positive-airway-pressure and positive-end-expiratory-pressure levels (cmH2 O) used in preterm infants (P = .021, and P = .032). Ethical and educational aspects were also similar. Conclusions: This survey provided information on neonatal resuscitation practices in a sam-ple of hospitals from all regions of Turkey and allowed us to see weaknesses in some fields. Although adherence to the guidelines was high among centers, further implementations are required in the areas of antenatal counseling, cord management, and circulation assessment in the delivery room. © 2023, AVES. All rights reserved.Item Concurrent breast cancer and IgG4-related orbital pseudotumor in a man(John Wiley and Sons Inc, 2024) Yüce Inel T.; Uslu S.; Bajin M.S.; Onen F.[No abstract available]Item Clinical and Demographic Characteristics of Treatment Requiring Retinopathy of Prematurity in Big Premature Infants in Turkiye: Report No. 1 (BIG-ROP Study)(S. Karger AG, 2024) Özdek Å.; Ozdemir H.B.; Ozen Tunay Z.; Bayramoglu S.E.; Alyamac Sukgen E.; Klr N.; Koç E.; Ekinci D.Y.; Sayin N.; Ceylan N.A.; Cebeci Z.; Çelik G.; Kizilay O.; Demir S.T.; Yildiz M.; Öztürk T.; Bekmez S.; Eris E.; Çömez A.; Mayali H.; Kabatas E.U.; Satirtav G.; Ögreden T.; Vural A.; Onur I.U.; Yeter D.Y.; Gönc T.; Tanidir S.T.; Akdogan M.; Çelemler P.; Beyazyildiz E.; Beyazyildiz Ö.; Acar D.E.; Özbay E.K.; Özcan Y.; Keles S.; Yildirim M.; Uzun A.; Dikci S.; Sari A.; Kara C.; Petriçli I.S.; Comba Ö.B.S.; Albayrak S.; Ersan B.A.; Bilgin B.; Çeliker H.; Sahin O.; Seymen Z.; Alaluf A.; Kaymak N.Z.; Oral A.Y.; Kerimoglu H.; Ünsal A.I.A.; Hirfanoglu I.M.; Tayman C.; Mert M.K.; Çetinkaya M.; Karatekin G.; Uslu S.; Özkan H.; Tüzün F.; Yildirim T.G.; Yurttutan S.; Dinlen N.F.; Bezirganoglu H.; Altinhan H.; Salihoglu Ö.; Tun G.; Karakurt D.G.; Bas A.Y.; Demiroglu Ö.B.; Aygün C.; Tekgündüz K.S.; Ceylan M.; Özdemir R.; Zübahiroglu U.; Özkiraz S.; Cömert S.; Akcan A.B.Introduction: The aim of the study was to analyse the clinical and demographic features of infants with gestational age (GA) of 32-37 weeks and birth weight (BW) of >1,500 g who developed treatment requiring retinopathy of prematurity (ROP). Methods: Data on the infants with a GA of 32-37 weeks and BW >1,500 g who developed treatment requiring ROP (TR-ROP) were collected retrospectively from the 33 ROP centres in Turkiye. GA, BW, type of hospital, neonatal intensive care units (NICUs) level, presence of an ophthalmologist and neonatologist in the same hospital, length of stay in NICU, duration of oxygen therapy, comorbidities, type of ROP, and timing for TR-ROP development were analysed. Results: A total of366 infants were included in the study. Mean GA and BW were 33 1 weeks and 1,896 316 g, respectively. Duration of hospitalization was 3-4 weeks in 46.8% of them. The first ROP examination was performed at postnatal 4-5 weeks in 80.3% of infants, which was significantly later in level 2 and lower NICUs and non-university clinics. At the first ROP examination, any stage of ROP was detected in 90.9% and TR-ROP was detected in 15.3% of the infants. The mean postnatal week of TR-ROP development was 6.16 2.04. Conclusion: Routine ROP screening thresholds need to be expanded in hospitals with suboptimal NICU conditions considering the development of TRROP in more mature and heavier preterm infants. The first ROP examination should be earlier than the fourth postnatal week. 2024 S. Karger AG, Basel. © 2024 S. Karger AG. All rights reserved.Item Fabry disease in familial Mediterranean fever according to the severity of the disease; [Enfermedad de Fabry en la fiebre mediterránea familiar según la gravedad de la enfermedad](Ediciones Doyma, S.L., 2024) Uslu S.; Kabadayi G.; Teke Kısa P.; Yüce Inel T.; Arslan Z.; Arslan N.; Akar S.; Onen F.; Sari I.Objectives: Mutations in the α-galactosidase A (GLA) gene result in Fabry disease (FD), a rare metabolic condition. FD patients present with heterogeneous clinical manifestations, which may overlap with systemic diseases including familial Mediterranean fever (FMF). The aim of this study was to determine the frequency of FD in patients with mild and severe FMF and to prevent misdiagnosis by increasing clinicians’ awareness. Methods: Based on Tel-Hashomer criteria, the study included a total of 91 FMF patients. Patients were divided into two groups according to the number of recurrent clinical episodes or failure to respond to maximum therapy: those with mild and severe forms of the disease. GLA gene mutations and α-GLA enzyme activity were assessed. Records of MEFV mutations, therapies and demographic characteristics were kept. Results: FD testing was performed on a cohort of 91 FMF patients, 54.9% had mild FMF, 45.1% had severe FMF, and only one patient in the mild FMF subgroup tested positive for FD. The patient was a 39-year-old woman with a history of recurrent abdominal pain, distal limb pain and fever. She had low GLA enzyme activity and a heterozygous GLA gene mutation. Conclusions: Our findings suggest that FD should be considered in the differential diagnosis of FMF, especially in individuals with unusual symptoms. © 2024 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de ReumatologíaItem Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study(Nature Research, 2024) Uslu S.; Gulle S.; Sen G.; Cefle A.; Yilmaz S.; Kocaer S.B.; Yuce Inel T.; Koca S.S.; Yolbas S.; Ozturk M.A.; Senel S.; Inanc N.; Dalkilic H.E.; Soysal Gunduz O.; Tufan A.; Akar S.; Birlik A.M.; Sari I.; Akkoc N.; Onen F.Clinical data on the use of tumour necrosis factor inhibitors (TNFi) in late-onset ankylosing spondylitis (LoAS) are limited. The present study aimed to evaluate efficacy, safety, and treatment adherence associated with the initial use of TNFi therapy in biologic naive patients diagnosed with LoAS. Patients whose age of onset was ≥ 45 years and < 45 years were classified as having LoAS and YoAS, respectively, based on the age of symptom onset. There were 2573 patients with YoAS and 281 LoAS. Baseline disease activity measures were similar between the groups. No significant differences were seen between the two groups in response to treatment and in remaining on the first TNFi at 6, 12 and 24 months. In the LoAS group, the analysis showed that TNFi discontinuation was linked to VAS pain score (HR 1.04; 95% CI 1.01–1.06). Patient groups had similar rates of adverse events (YoAS: 8.7% vs. LoAS: 11.7%). In both biologic naive LoAS and YoAS patients, the study showed that the initial TNFi therapy was equally effective and safe. © The Author(s) 2024.Item Assessment of liver and kidney function in patients with ankylosing spondylitis on long-term non-steroidal anti-inflammatory drug therapy(Page Press Publications, 2024) Sülükcü S.; Uslu S.Objective. This study aimed to analyze the status of liver [aspartate aminotransferase (AST) and alanine ami-notransferase (ALT)] and kidney (serum creatinine) function in ankylosing spondylitis (AS) patients assuming continuously non-steroidal anti-inflammatory drugs (NSAIDs) alone over a long period. Methods. Between 2013 and 2022, there were records of 385 AS patients. Of them, 56 were receiving only NSAIDs, and the files of these patients were retrospectively analyzed. Demographic and clinical characteristics were collected. Blood tests, including serum creatinine, AST, and ALT, were assessed at each visit. Results. Of the 56 patients, 39 were male. The mean age was 45.30 years, and the follow-up period was 9.80 years. Of them, 44.6% used indomethacin, 26.8% naproxen, 17.9% diclofenac, 5.4% acemetacin, 3.6% meloxi-cam, and 1.8% celecoxib. The mean baseline serum creatinine was 0.71 mg/dL. The mean baseline serum AST and ALT were 19.6 u/L and 22.9 u/L, respectively. Baseline creatinine, AST, and ALT were not statistically significantly different between sexes. There was a statistically significant difference between mean creatinine concentrations at baseline and at year 3. One patient on naproxen discontinued treatment due to elevated cre-atinine. The creatinine level decreased during the patient’s follow-up. Liver enzymes above 3 times the normal value were not seen in any patient. Conclusions. Based on real-world data, long-term use of NSAIDs has generally not led to acute liver and kidney injury or progressive impairment of hepatorenal function requiring discontinuation of treatment. © 2024, Page Press Publications. All rights reserved.Item Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis(Multidisciplinary Digital Publishing Institute (MDPI), 2024) Uslu S.; Gülle S.; Sen G.; Capar S.; Senel S.; Dalkılıc E.; Akar S.; Koca S.S.; Tufan A.; Yazici A.; Yilmaz S.; Inanc N.; Birlik M.; Solmaz D.; Cefle A.; Goker B.; Direskeneli H.; Yolbas S.; Steen Krogh N.; Yilmaz N.; Erten S.; Bes C.; Soysal Gündüz O.; Oztürk M.A.; Haznedaroglu S.; Yavuz S.; Onen F.; Sari I.Background/Objectives: CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in patients with AS undergoing first-line (1st-line) and later (≥2nd-line) treatment in clinical practice. Methods: We performed an observational cohort study that included AS patients based on the biological drug database in the TURKBIO Registry between 2014 and 2021. The patients were divided into two groups: those receiving CT-P13 as first-line treatment or as a switch (≥2nd-line) from another TNF inhibitor (TNFi). Standard disease activity metrics were used to assess the effectiveness of CT-P13, and drug retention rates were investigated. Results: There were 179 AS patients using CT-P13 (47.4% male, mean age: 42.9 ± 11.3 years). Of these patients, 123 (68.7%) were receiving CT-P13 as a first-line treatment. The mean length of treatment was 3.5 years. CT-P13 drug retention rates in the general patient population were 58.6% and 48.2% in the first-line and ≥second-line treatment, respectively, after 3 years of follow-up. The most common reason for CT-P13 treatment discontinuation was lack of efficacy. The first-line CT-P13 group had statistically substantially higher ASAS20/40 response rates at three and six months. Nonetheless, both groups’ response rates at one year were comparable. Conclusions: In this real-world data analysis, AS patients who were TNFi naïve (1st-line) and subsequently treated (≥2nd-line) with CT-P13 showed encouraging drug retention rates with acceptable long-term effectiveness and safety. © 2024 by the authors.Item A life-threatening manifestation of granulomatosis with polyangiitis: Subglottic stenosis(Turkish League Against Rheumatism (TLAR), 2024) Inel T.Y.; Uslu S.[No abstract available]Item Evaluation of irritable bowel syndrome in patients with systemic sclerosis based on Rome IV criteria; [Bewertung des Reizdarmsyndroms bei Patienten mit systemischer Sklerose nach den Rom-IV-Kriterien](Georg Thieme Verlag, 2024) Tuncel E.T.; Sahinoglu I.; Uslu S.Objectives The gastrointestinal system is the second most frequently affected organ system in patients with systemic sclerosis (SSc). Patients with SSc experience gastrointestinal dysmotility due to pathophysiological changes, including alterations in intestinal microbiota, inflammation, fibrosis, vascular ischaemia, and muscle atrophy. The aim of this study was to determine the prevalence of functional gastrointestinal disorders in patients with SSc. Material and Methods This study included 66 patients with SSc. Demographic data, including age, gender, and clinical findings, were recorded. The Rome IV criteria were used to assess gastrointestinal complaints. Results A total of 66 (F = 61, M = 5) patients (limited cutaneous SSc (lcSSc = 31), diffuse cutaneous SSc (dcSSc = 35)) were included in this study. In lcSSs patients, the prevalence of functional dyspepsia, irritable bowel syndrome (IBS), constipation, and diarrhoea was 29.0 %, 12.9 %, 6.5 % and 3.2 %, respectively, whereas in dcSSc, the prevalence of these disorders was 37.1 %, 8.6 %, 8.6 %, and 0.0 %, respectively. There was no statistically significant difference regarding the presence of functional gastrointestinal disorders between lcSSc and dcSSc patients. When patients with SSc were compared based on functional gastrointestinal disorders, no significant differences were observed between the groups in terms of mean age, disease duration, smoking, lung involvement, and presence of body mass index ≥ 25. Conclusion Alterations in gut microbiota and inflammatory changes have been proposed as contributing factors in IBS. Chronic inflammatory diseases, such as SSc, may therefore predispose individuals to its development. In our study, IBS was found in 10.7 % of the SSc patients. To identify patients at high risk of IBS, further studies are required. © 2024. Thieme. All rights reserved.Item Case report: Coexistence of takotsubo syndrome and severe mononeuritis multiplex in rheumatoid vasculitis(John Wiley and Sons Inc, 2024) Acar E.A.; Uslu S.; Gemici Y.I.; Cetin N.; Temiz P.; Gündüz O.S.[No abstract available]Item Heerfordt’s syndrome: a rare manifestation of neurosarcoidosis(Springer Science and Business Media Deutschland GmbH, 2024) Sahinoğlu I.; Uslu S.[No abstract available]Item Salt-and-pepper appearance of the skin in systemic sclerosis; [Aspecto sal y pimienta de la piel en la esclerosis sistémica](Ediciones Doyma, S.L., 2024) Tasgöz F.C.; Ali Acar E.; Kaçar M.; Soysal Gündüz Ö.; Uslu S.[No abstract available]Item Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data results(Turkish League Against Rheumatism (TLAR), 2024) Uslu S.; Gülle S.; Urak Ö.; Şen G.; Dalkılıç E.; Şenel S.; Akar S.; İnanç N.; Cefle A.; Avşar A.K.; Yolbaş S.; Yılmaz S.; Gündüz Ö.S.; Sarı İ.; Birlik M.; Akkoç N.; Önen F.Objectives: This study aims to investigate the effect of age on disease activity and biological treatment in patients with ankylosing spondylitis (AS). Patients and methods: A total of 811 AS patients registered in the TURKBIO registry database between 2011 and 2019 were categorized according to their age at the time of entry into the registry and assigned to one of two groups: young patients, defined as <60 years of age (n=610), and those aged ≥60 years (n=201) were recorded as elderly patients. Demographic, clinical, and laboratory characteristics, along with disease activity markers and other follow-up parameters, as well as current and prior treatments, were electronically recorded during each visit using open-source software. Results: The mean age of the elderly patients was 67±5.8 years, while the mean age of the younger patients was 49.2±10.9 years. Male predominance was lower in the older AS group compared to the younger AS group (p=0.002). During follow-up period, 397 patients (comprising 318 young and 79 elderly individuals) had a history of using at least one biological disease-modifying agent (bDMARD). There was no significant difference between the groups in terms of DMARD and bDMARD-use distributions. First tumor necrosis factor inhibitor (TNFi) retention rates were found to be similar in both groups over 10 years of follow-up. Adverse events were found to be similar in young (19.9%) and elderly (26.8%) AS patients. Conclusion: Research in the TURKBIO cohort reveals that both older and younger patients with AS exhibited similar disease activity levels with comparable treatment approaches. Moreover, the results of TNFi treatments in elderly patients were the same as those observed in younger patients, with no notable increase in safety concerns. © 2024, Turkish League Against Rheumatism (TLAR). All rights reserved.Item Melorheostosis: A rare disease of the bone(John Wiley and Sons Inc, 2024) Karakas A.; Uslu S.[No abstract available]Item Evaluation of lacrimal gland vascularization using superb microvascular imaging: A potential diagnostic tool in Sjögren's syndrome(Oxford University Press, 2025) Salbas C.S.; Uslu S.; Salbas E.Objectives: The aim of this study is to evaluate the superb microvascular imaging (SMI) findings of the lacrimal glands for the sonographic diagnosis of primary Sjögren's syndrome (pSS). Methods: Twenty-one patients with pSS and 20 healthy groups were evaluated. Dry eye symptoms and their effects on vision-related functions were evaluated with McMonnies and Ocular Surface Disease Index (OSDI) questionnaires. Lacrimal glands were evaluated by power Doppler ultrasonography (PDUS), colour Doppler ultrasonography (CDUS), and SMI. Results: Dry eye symptoms, as determined by McMonnies and OSDI, were significantly more severe in patients with pSS than in the control group (P =. 001 and P =. 021, respectively). Lacrimal gland vascular activity rates and hypoechoic areas were significantly higher in pSS patients compared to the control group (P <. 05). The detection rates of the degree of vascularity in the lacrimal glands of patients with pSS were higher with SMI compared to CDUS and PDUS. In addition, SMI positively correlated with CDUS, PDUS, OSDI, and McMonnies. Conclusions: Evaluation of the lacrimal gland by the SMI was found to be excellent in predicting the likelihood of individuals having pSS compared to CDUS and PDUS. This technique may serve as a reliable and noninvasive adjunctive tool for assessing the degree of lacrimal vascularity in pSS. © 2024 Japan College of Rheumatology. Published by Oxford University Press. All rights reserved.Item ‘Pencil-in-cup’ deformity in systemic sclerosis–rheumatoid arthritis overlap syndrome(Taylor and Francis Ltd., 2025) Acar E.A.; Uslu S.; Soysal Gündüz O.; Pirildar T.[No abstract available]